Predictors of 3-year overall survival
| Covariates . | RR . | 95% CI . | P Value . |
|---|---|---|---|
| Malformative syndrome | |||
| Limited (<3 sites) | 1.00 | ||
| Extensive (≥3 sites) | 2.96 | 1.54-5.71 | .001 |
| Donor gender | |||
| Male | 1.00 | ||
| Female | 2.33 | 1.19-4.54 | .01 |
| Androgens before transplant | |||
| No | 1.00 | ||
| Yes | 2.11 | 1.07-4.15 | .03 |
| Recipient cytomegalovirus serology before transplant | |||
| Negative | 1.00 | ||
| Positive | 1.90 | 1.00-3.60 | <.05 |
| Covariates . | RR . | 95% CI . | P Value . |
|---|---|---|---|
| Malformative syndrome | |||
| Limited (<3 sites) | 1.00 | ||
| Extensive (≥3 sites) | 2.96 | 1.54-5.71 | .001 |
| Donor gender | |||
| Male | 1.00 | ||
| Female | 2.33 | 1.19-4.54 | .01 |
| Androgens before transplant | |||
| No | 1.00 | ||
| Yes | 2.11 | 1.07-4.15 | .03 |
| Recipient cytomegalovirus serology before transplant | |||
| Negative | 1.00 | ||
| Positive | 1.90 | 1.00-3.60 | <.05 |
RR indicates relative risk; CI, confidence interval.